Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Barrons10/16/2026Negative
NVAX
Novavax IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.86B
P/E Ratio
—
EPS
$-1.58
Beta
2.44
52W High
$13.39
52W Low
$6.20
50-Day MA
$10.02
200-Day MA
$9.16
Dividend Yield
—
Profit Margin
-59.90%
Forward P/E
2.58
PEG Ratio
1.32
About Novavax Inc
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | $413.80M |
| Gross Profit (TTM) | $-10.58M |
| EBITDA | $-101.55M |
| Operating Margin | -89.60% |
| Return on Equity | -898.00% |
| Return on Assets | -6.51% |
| Revenue/Share (TTM) | $2.54 |
| Book Value | $-1.16 |
| Price-to-Book | 41.23 |
| Price-to-Sales (TTM) | 4.49 |
| EV/Revenue | 3.186 |
| EV/EBITDA | 1.72 |
| Quarterly Earnings Growth (YoY) | -38.10% |
| Quarterly Revenue Growth (YoY) | -76.30% |
| Shares Outstanding | $164.95M |
| Float | $144.57M |
| % Insiders | 5.05% |
| % Institutions | 67.53% |
Historical Volatility
HV 10-Day
152.58%
HV 20-Day
107.46%
HV 30-Day
92.63%
HV 60-Day
74.78%
HV Rank
98.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($14.22 target)
5
Buy1
Hold1
Sell2
Strong SellLatest News
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.
24/7 Wall Street10/16/2026Negative
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.
Zacks Investment Research10/12/2026Positive
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%.
24/7 Wall Street10/9/2026Positive
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Investment Research10/9/2026Positive
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $11.27, marking a -10.31% move from the previous day.
Zacks Investment Research10/6/2026Negative
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low.
24/7 Wall Street10/6/2026Negative
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks Investment Research10/6/2026Positive
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.
24/7 Wall Street10/5/2026Positive
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research9/28/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVAX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026